Literature DB >> 25828084

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib.

Claire Harrison1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25828084      PMCID： PMC4380710          DOI： 10.3324/haematol.2015.124099

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  24 in total

1.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Authors:  Luzhou Xing; Zhenpeng Dai; Ali Jabbari; Jane E Cerise; Claire A Higgins; Weijuan Gong; Annemieke de Jong; Sivan Harel; Gina M DeStefano; Lisa Rothman; Pallavi Singh; Lynn Petukhova; Julian Mackay-Wiggan; Angela M Christiano; Raphael Clynes
Journal:  Nat Med       Date:  2014-08-17       Impact factor: 53.440

2.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.

Authors:  Silvia Spoerl; Nimitha R Mathew; Michael Bscheider; Annette Schmitt-Graeff; Sophia Chen; Tony Mueller; Mareike Verbeek; Julius Fischer; Vera Otten; Martina Schmickl; Kristina Maas-Bauer; Jürgen Finke; Christian Peschel; Justus Duyster; Hendrik Poeck; Robert Zeiser; Nikolas von Bubnoff
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.

Authors:  A Tefferi; P Guglielmelli; T L Lasho; G Rotunno; C Finke; C Mannarelli; A A Belachew; A Pancrazzi; E A Wassie; R P Ketterling; C A Hanson; A Pardanani; A M Vannucchi
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

Review 7.  Safety evaluation of ruxolitinib for treating myelofibrosis.

Authors:  Sofia Galli; Donal McLornan; Claire Harrison
Journal:  Expert Opin Drug Saf       Date:  2014-06-04       Impact factor: 4.250

8.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

9.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

10.  Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.

Authors:  Paola Guglielmelli; Flavia Biamonte; Giada Rotunno; Valentina Artusi; Lucia Artuso; Isabella Bernardis; Elena Tenedini; Lisa Pieri; Chiara Paoli; Carmela Mannarelli; Rajmonda Fjerza; Elisa Rumi; Viktoriya Stalbovskaya; Matthew Squires; Mario Cazzola; Rossella Manfredini; Claire Harrison; Enrico Tagliafico; Alessandro M Vannucchi
Journal:  Blood       Date:  2014-01-23       Impact factor: 25.476
View more
  6 in total

Review 1.  Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.

Authors:  Naveen K R Chalakur-Ramireddy; Suresh B Pakala
Journal:  Biosci Rep       Date:  2018-01-30       Impact factor: 3.840

2.  The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.

Authors:  Kazuhiko Ikeda; Koki Ueda; Takahiro Sano; Kazuei Ogawa; Takayuki Ikezoe; Yuko Hashimoto; Soji Morishita; Norio Komatsu; Hitoshi Ohto; Yasuchika Takeishi
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

Review 3.  Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.

Authors:  Elena Maria Elli; Claudia Baratè; Francesco Mendicino; Francesca Palandri; Giuseppe Alberto Palumbo
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

Review 4.  Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

Authors:  Vibe Skov
Journal:  Cancers (Basel)       Date:  2020-08-06       Impact factor: 6.639

Review 5.  Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.

Authors:  Saima Usman; Ahmad Jamal; Muy-Teck Teh; Ahmad Waseem
Journal:  Front Oral Health       Date:  2021-01-25

Review 6.  JAK-STAT signaling in cancer: From cytokines to non-coding genome.

Authors:  Jan Pencik; Ha Thi Thanh Pham; Johannes Schmoellerl; Tahereh Javaheri; Michaela Schlederer; Zoran Culig; Olaf Merkel; Richard Moriggl; Florian Grebien; Lukas Kenner
Journal:  Cytokine       Date:  2016-06-24       Impact factor: 3.861
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.